Androgen deprivation of the prohormone convertase-310 human prostate cancer model system induces neuroendocrine differentiation

Cancer Research

Volumn 60, Issue 3, 2000, Pages 741-748

  Jongsma, Johan ^a   Oomen, Monique H ^a   Noordzij, Marinus A ^a   Van Weerden, Wytske M ^a   Martens, Gerard J M ^b   Van Der Kwast, Theodorus H ^a   Schröder, Fritz H ^a   Van Steenbrugge, Gert J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; FURIN; GASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; SECRETOGRANIN III; SEROTONIN; UNCLASSIFIED DRUG; ANDROGEN; ANDROGEN RECEPTOR; CHROMOGRANIN; MIXED FUNCTION OXIDASE; MULTIENZYME COMPLEX; PEPTIDYLGLYCINE MONOOXYGENASE;

ANDROGEN RELEASE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH REGULATION; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; CYTOLOGY; HUMAN; MALE; NEOPLASM; NEUROSECRETION; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR;

ANDROGENS; ANIMALS; CELL DIFFERENTIATION; CHROMOGRANIN A; CHROMOGRANINS; HUMANS; MALE; MICE; MICE, NUDE; MIXED FUNCTION OXYGENASES; MULTIENZYME COMPLEXES; NEOPLASMS, HORMONE-DEPENDENT; NEUROSECRETORY SYSTEMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0034131990     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Abrahamsson, P. A. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate, 6 (Suppl.): 3-8, 1996.
2. Krijnen, J. L. M., Janssen, P. J. A., Ruizeveld de Winter, J. A., van Krimpen, H., Schröder, F. H., and van der Kwast, T. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry, 100: 393-398, 1993.
3. Bonkhoff, H., Stein, U., and Remberger, K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum. Pathol., 26: 167-170, 1995.
4. di-Sant'Agnese, P. A. Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol., 23: 287-296, 1992.
5. di-Sant'Agnese, P. A. Neuroendocrine differentiation in prostatic carcinoma. Cancer (Phila.), 75 (Suppl.): 1850-1859, 1995.
6. Noordzij, M. A., van Steenbrugge, G. J., van der Kwast, T., and Schröder, F. H. Neuroendocrine cells in the normal, hyperplastic, and neoplastic prostate. Urol. Res., 22: 333-341, 1995.
7. Noordzij, M. A., van der Kwast, T., van Steenbrugge, G. J., Hop, W. J. C., and Schröder, F. H. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long term follow-up study with patients treated by radical prostatectomy. Int. J. Cancer, 62: 252-258, 1995.
8. Abrahamsson, P. A., Wadström, L. B., Alumets, J., Falkmer, S., and Grimelius, L. Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol. Res. Pract., 181: 675-683, 1986.
9. Aprikian, A. G., Cordon-Cardo, C., Fair, W. R., and Reuter, V. E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer (Phila.), 71: 3952-3965, 1993.
10. Xue, Y., Verhofstad, A., Lange, W., Smedts, F., Debruyne, F., de la Rosette, J., and Schalken, J. Prostatic neuroendocrine cells have a unique keratin expression and do not express Bcl-2. Am. J. Pathol., 151: 1759-1765, 1997.
11. Abrahamsson, P. A., Falkmer, S., K, F. Ö., and Grimelius, L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker." Pathol. Res. Pract., 185: 373-380, 1989.
12. Hendy, G. N., Bevan, S., Mattei, M. G., and Mouland, A. J. Chromogranin A. Clin. Investig. Med., 18: 47-65, 1995.
13. Schmid, K. W., Helpap, B., Totsch, M., Kirchmair, R., Dockhorn-Dworniczak, B., Bocker, W., and Fischer-Colbrie, R. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic, and neoplastic prostate. Histopathology, 24: 233-239, 1994.
14. O'Connor, D., and Deftos, L. Secretion of chromogranin A by peptide producing endocrine neoplasias. N. Engl. J. Med., 314: 1145-1151, 1986.
15. Bonkhoff, H., Stein, U., and Remberger, K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum. Pathol., 25: 42-46, 1994.
16. Bonkhoff, H., Stein, U., and Remberger, K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate, 24: 114-118, 1994.
17. Cohen, M. K., Arber, D. A., Coffield, S., Keegan, G. T., McClintock, J., and Speights, V. O. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer (Phila.), 74: 1899-1903, 1994.
18. Colombel, M., Olsson, C. A., Ng, P. Y., and Buttyan, R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res., 52: 4313-4319, 1992.
19. Jongsma, J., Oomen, M., Noordzij, M., Van Weerden, W., Martens, G., Van der Kwast, T., Schröder, F., and Van Steenbrugge, G. The kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am. J. Pathol., 154: 543-551, 1998.
20. Jiborn, T., Bjartell, A., and Abrahamsson, P-A. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology, 51: 585-589, 1998.
21. Krijnen, J., Bogdanowitz, J., Seldenrijk, C., Mulder, P., and Van der Kwast, T. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J. Urol., 158: 171-174, 1997.
22. Holthuis, J. C. M., and Martens, G. J. M. The neuroendocrine proteins secretogranin II and III are regionally conserved and coordinately expressed with proopiomelanocortin in Xenopus intermediate pituitary. J. Neurochem., 66: 2248-2256, 1996.
23. Smeekens, S. P., Montag, A. G., Thomas, G., Albiges-Rizo, C., Carrol, R., Benig, M., Philips, L. A., Martin, S., Ohagi, S., Gardner, P., Swift, H., and Steiner, D. F. Pro-insulin processing by the sutilisin-related pro-protein convertases furin, PC2, and PC3. Proc. Natl. Acad. Sci. USA, 89: 8822-8826, 1992.
24. Tucker, J. D., Dhanvantari, S., and Brubaker, P. L. Pro-glucagon processing in islet and intestinal cell lines. Regul. Pept., 62: 29-35, 1996.
25. Holthuis, J., Janssen, E., Van Riel, M., and Martens, G. Molecular probing of the secretory pathway in peptide hormone producing cells. J. Cell Sci., 108: 3295-3305, 1995.
26. Braks, J. A. M., Broers, C. A. M., Danger, J. M., and Martens, G. J. M. Structural organization of the gene encoding the neuroendocrine chaperone 7B2. Eur. J. Biochem., 236: 60-67, 1996.
27. Martens, G. J. M., Bussemakers, M. J. G., Ayoubi, T. A. Y., and Jenks, B. G. The novel pituitary polypeptide 7B2 is a highly-conserved protein coexpressed with proopiomelanocortin. Eur. J. Biochem., 181: 75-79, 1989.
28. Sigafoos, J., Chestnut, W. G., Merril, B. M., Taylor, L. C. E., Diliberto, E. J., and Viveros, O. H. Novel peptides from adrenomedullary chromaffin vesicles. J. Anat., 183: 253-264, 1993.
29. Vos, M. D., Jones, J. E., and Treston, A. M. Human peptidylglycine alpha-amidating monooxygenase transcripts derived by alternative mRNA splicing of an unreported exon. Gene, 163: 307-311, 1995.
30. Vos, M. D., Scott, F. M., Iwai, N., and Treston, A. M. Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype. J. Cell Biochem., 27: 1-12, 1996.
31. Huttner, W. B., and Natori, S. Helper proteins for neuroendocrine secretion. Curr. Biol., 5: 242-245, 1995.
32. Eib, D. W., and Martens, G. J. M. A novel transmembrane protein with epidermal growth factor and follistatin domains expressed in the hypothalamo-hypophyssial axis of Xenopus laevis. J. Neurochem., 67: 1047-1055, 1996.
33. Romijn, J., Erkens-Schulze, S., and Schröder, F. Perspectives of the use of tissue culture models as an alternative to human prostate cancer xenografts in nude mice. Contrib. Oncol., 51: 209-231, 1996.
34. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042-3046, 1996.
35. Liu, A. Y., Corey, E., Bladou, F., Lange, P. H., and Vesella, R. L. Prostatic cell lineage markers: emergence of Bcl2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int. J. Cancer, 65: 85-89, 1996.
36. van Weerden, W. M., de Ridder, C. M. A., Verdaasdonk, C. L., Romijn, J. C., van der Kwast, T. H., Schröder, F. H., and van Steenbrugge, G. J. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol., 149: 1055-1062, 1996.
37. Noordzij, M. A., van Weerden, W. M., van der Kwast, T. H., Abrahamsson, P. A., Gershagen, S., Schröder, F. H., and van Steenbrugge, G. J. Neuroendocrine differentiation in human prostatic tumor models. Am. J. Pathol., 149: 859-871, 1996.
38. van Steenbrugge, G., Groen, M., de Jong, F., and Schröder, F. The use of steroid-containing silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles. Prostate, 5: 639-647, 1984.
39. Limon, J., Lundgren, R., Elfving, P., Heim, S., Kristofferson, U., Mandahl, N., and Mitelman, F. An improved technique for short-term culturing of human prostatic adenocarcinoma tissue for cytogenetic analysis. Cancer Genet. Cytogenet., 46: 191-199, 1990.
40. Holthuis, J., Jansen, E., and Martens, G. Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway. J. Biol. Chem., 271: 17755-17760, 1996.
41. Shi, S. R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues; an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39: 741-748, 1991.
42. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
43. Ruizeveld de Winter, J. A., van Weerden, W. M., Faber, P. W., van Steenbrugge, G. J., Trapman, J., Brinkmann, A. O., and van der Kwast, T. Regulation of androgen receptor expression in the human heterotransplantable prostate carcinoma PC-82. Endocrinology, 131: 3045-3050, 1992.
44. van der Kwast, T., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C. J., Mulder, E., Boersma, W., and Trapman, J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer, 48: 189-193, 1991.
45. Gil-Diez de Medina, S., Salomon, L., Colombel, M., Abbou, C., Bellot, J., Thierry, J., Radvanyi, F., Van der Kwast, T., and Chopin, D. Modulation of cytokeratin subtype EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum. Pathol., 29: 1005-1012, 1998.
46. Koivisto, P., Kolmer, M., Visakorpi, T., and Kallioniemi, O-P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol., 152: 1-9, 1998.
47. Esquenet, M., Swinnen, J., Heyns, W., and Verhoeven, G. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. J. Steroid Biochem. Mol. Biol., 62: 391-399, 1997.
48. Barbosa, J., Gill, B., Takiyyuddin, M., and O'Conner, D. Chromogranin A. Post-translational modifications in secretory granules. Endocrinology, 128: 174-190, 1991.
49. Eskeland, N., Zhou, A., Dinh, T., Wu, H., Parmer, R., Mains, R., and Connor, D. Chromogranin A processing and secretion. J. Clin. Investig., 98: 148-156, 1996.
50. Metz-Boutigue, M-H., Garcia-Sablone, P., Hogue-Angeletti, R., and Aunis, D. Intracellular and extracellular processing of chromogranin A (Determination of cleavage sites). Eur. J. Biochem., 217: 247-257, 1993.
51. Saldise, L., Martinez, A., Montuenga, L. M., Treston, A., Springall, D. R., Polak, J. M., and JJ, V. Distribution of peptidyl-glycine α-amidating mono-oxygenase (PAM) enzymes in normal human lung and epithelial tumors. J. Histochem. Cytochem., 44: 3-12, 1996.
52. Semenza, G. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J. Lab. Clin. Med., 131: 207-214, 1998.
53. Zhong, H., Agani, F., Baccala, A., Laughner, E., RiosecoCamacho, N., Isaacs, W., Simons, J., and Semenza, G. Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Res., 58: 5280-5284, 1998.
54. Chan, J., Stampfer, M., Giovanucci, E., Gann, P., Ma, J., Wilkinson, P., Hennekens, C., and Pollak, M. Plasma Insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science (Washington DC), 279: 563-566, 1998.
55. Hobisch, A., Eder, I., Putz, T., Horninger, W., Bartsch, G., Klocker, H., and Culig, Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res., 58: 4640-4645, 1998.